| Literature DB >> 16046056 |
Ana C Cunha1, Bernd Weigle, Andrea Kiessling, Michael Bachmann, E Peter Rieber.
Abstract
Activation of immune defense mechanisms against tumor antigens appears to be a promising therapeutic option for advanced prostate cancer (PCa). Specific immunotherapy critically depends on target antigens that are selectively expressed in the tumorous and optional in the normal prostate tissue in sufficient amounts. Although several prostate antigens have been described and some have already been used in clinical trials, a detailed comparative evaluation of their tissue-specificity and expression levels is still lacking. We determined the transcript levels of eight prostate targets (PSA, PAP, PSCA, PSGR, Prostein, PSMA, AIbZIP, trp-p8) in 16 different tissues by quantitative PCR and calculated a tissue-specificity index (TSI) for each molecule. Besides a preferential expression in prostate for all targets, striking differences in the expression levels and TSI were revealed which may be important for the selection of appropriate antigens for immunotherapy of PCa.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16046056 DOI： 10.1016/j.canlet.2005.05.021
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679